In HER2-negative advanced gastric cancer, the phase 1b/2 COMPASSION-04 trial demonstrated an objective response rate (ORR) of 52.1% and a median overall survival (OS) of 17.5 months (CTR20182027). This evidence concerns the gene ERBB2 and gastric cancer.